resource source identifier antibodies polyclonal rabbit anti focal adhesion kinase anti fak cell signaling technologies (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
86
Structured Review
Cell Signaling Technology Inc
resource source identifier antibodies polyclonal rabbit anti focal adhesion kinase anti fak cell signaling technologies
Resource Source Identifier Antibodies Polyclonal Rabbit Anti Focal Adhesion Kinase Anti Fak Cell Signaling Technologies, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+fak/pm41790552-244-2-12
Average 86 stars, based on 1 article reviews
Resource Source Identifier Antibodies Polyclonal Rabbit Anti Focal Adhesion Kinase Anti Fak Cell Signaling Technologies, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+fak/pm41790552-244-2-12
Average 86 stars, based on 1 article reviews
resource source identifier antibodies polyclonal rabbit anti focal adhesion kinase anti fak cell signaling technologies - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Western Blot:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Recombinant:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Staining:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Membrane:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Bicinchoninic Acid Protein Assay:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Gel Extraction:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Mutagenesis:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Software:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Expressing:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Plasmid Preparation:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Generated:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Construct:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Transduction:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Activation Assay:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Control:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Microscopy:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Migration:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Stable Transfection:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Activity Assay:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Immunostaining:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Immunofluorescence:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Labeling:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Binding Assay:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Virus:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: CCK-8 Assay:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: cDNA Synthesis:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: TUNEL Assay:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Apoptosis Assay:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Mass Spectrometry:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Sequencing:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: shRNA:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Protease Inhibitor:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Lysis:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Transfection:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Electron Microscopy:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Immunodepletion:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Cloning:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Protein Purification:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Endotoxin Assay:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Bradford Assay:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Isolation:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Blocking Assay:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: Incubation:Article Title: Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas Article Snippet: The following antibodies were used in this study: Article Title: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene Article Snippet: Article Title: Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway Article Snippet: Article Title: PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Article Snippet: The following antibodies were used in this study: |